As 2018 begins, John McCamant, editor of Medical Technology Stock Letter, reviews several 2017 top performers, discusses the turnaround at the FDA, and profiles one company with an innovative non-statin LDL cholesterol in the pipeline.
Top Stock Pickers of 2017: Biotechnology expert John McCamant deserves special recognition; his top pick from last year rose an astounding 519%. We’ve asked John, and all these other outstanding advisors, to share their updated opinions on these top performing stocks from last year’s Top Picks 2017 report.
November 17, 2016 Opinion : 10 biotech companies ripe for a buyout, courtesy of Donald Trump (11-17-16) The Republican sweep of Washington has generated a ton of enthusiasm for biotech stocks. They’re up 10% to 15% since the elections. As a result, biotech analysts’ phones are ringing off the hook again after a depressingly bleak […]
The immediate reaction of a widely unexpected Republican sweep was a huge across the board rally in health care stocks. While it is still very early make definitive conclusions, several positive impacts have resulted in a major reversal of sentiment. Today’s impressive rally (NBI +8%) is a likelihood of some combination of the following macro fundamental and technical changes that are expected to occur with a new, right leaning administration.